Biogen Inc. (BIIB) Earnings Call Transcript & Summary

February 6, 2026

NASDAQ US Health Care Biotechnology earnings 64 min

What were the key takeaways from Biogen Inc.'s February 6, 2026 earnings call?

Biogen Inc. reported a strong fourth quarter and full year 2025, with total revenue of $9.9 billion, reflecting a 2% increase year-over-year. The company achieved a non-GAAP diluted EPS of $15.28 for the full year, slightly above guidance. Management signaled a cautious outlook for 2026, expecting total revenue to decline by a mid-single-digit percentage, primarily due to competitive pressures in the MS segment, while growth products are anticipated to partially offset this decline.

What topics did Biogen Inc. cover?

  • Growth Products Performance: Biogen's growth products generated $3.3 billion in fiscal 2025, up 19% year-over-year. Management noted, "we're principally focused on our growth products," which include VUMERITY, LEQEMBI, and others, indicating strong commercial execution.
  • Pipeline Advancements: The company highlighted significant progress in its pipeline, with multiple key readouts expected in 2026. Chris Viehbacher stated, "the big story of 2025 is really the advance we've made in our pipeline," emphasizing the potential for new product launches.
  • LEQEMBI Market Leadership: LEQEMBI continues to dominate the anti-amyloid therapy market with over 60% market share. Management indicated that the product's "persistency data suggests that we have about a 70% persistency," which bodes well for future sales growth.
  • 2026 Guidance: Biogen expects full year non-GAAP diluted EPS to be between $15.25 and $16.25, reflecting growth compared to 2025. However, total revenue is projected to decline by a mid-single-digit percentage due to competitive pressures in the MS segment.
  • Cost Management: The company achieved a non-GAAP R&D expense reduction of 10% for the full year 2025, attributed to portfolio prioritization initiatives. CFO Robin Kramer noted, "disciplined expense management enabled robust cash flow generation," highlighting effective cost control.

What were Biogen Inc.'s February 6, 2026 results?

  • Total Revenue: $9.9B (up 2% YoY)
  • Non-GAAP EPS: $15.28 (above guidance)
  • Growth Products Revenue: $3.3B (up 19% YoY)
  • Free Cash Flow: $2.1B (for full year 2025)
  • LEQEMBI Revenue Q4: $134M (up 54% YoY)
  • SPINRAZA Revenue Q4: $356M (down 2% YoY)

Biogen's strong performance in 2025, driven by growth products and pipeline advancements, is overshadowed by cautious guidance for 2026 due to expected revenue declines in the MS segment. Investors should monitor upcoming product approvals and pipeline readouts as potential catalysts, while remaining aware of competitive pressures and market dynamics.

Earnings Call Speaker Segments

Ruth

executive
#1

Hold on, please. Good morning. This is Ruth, and I'll be handling the conference lines for you today. Right now, I'd like to extend a welcome to each of you joining the Biogen Fourth Quarter and Full Year 2025 Earnings Call and Business Update. Every line has been muted so that background noise doesn't interfere. Once the speakers have finished their remarks, we'll open a question and answer session. Kindly keep to a single question so that others also have time to ask theirs. Should you need to ask anything further, just press star 1 once more and you'll be placed back in the queue. This conference is being recorded today. Thank you. At this point, I'm handing the conference to Mr. Tim Power, Head of Investor Relations. Mr. Power, the conference is yours to begin.

Tim Power

executive
#2

Thank you, Ruth, and hello everybody on this morning's call. It's a pleasure to have you join Biogen's discussion of results for the fourth quarter and the entire 2025 fiscal year. Statements we make today looking ahead carry risks and uncertainties, and because of those, actual outcomes could wind up differing materially from what those statements suggest. A full accounting of risk factors appears in our SEC filings, and we urge you to go through them. You can locate our earnings release, materials tied to our results, and the reconciliations of GAAP to non-GAAP figures we mention today within the Investors area of biogen.com. Slides we intend to reference during this call have likewise been placed on our website. Joining me on today's call are Christopher Viehbacher, our President and Chief Executive Officer; Dr. Priya Singhal, who leads Development; and Robin Kramer, our Chief Financial Officer. After a few opening remarks from us, we'll transition into the Q&A portion. So that we can address as many questions as possible, we kindly request that each of you ask only one; and with that, I'll turn things over to Christopher Viehbacher.

Christopher Viehbacher

executive
#3

Thanks, Tim. Morning, everyone, and thanks for joining Biogen’s Q4 earnings call. We had a strong finish to the year with a really solid fourth quarter, and overall I’d say we closed out the year in a very satisfying way. We came in just a bit above the top end of our guidance. And as we look at the business, our main focus has been on the growth products, which brought in $3.3 billion during fiscal 2025. That’s a 19% increase. Now, you’ll see that VUMERITY is now included among our growth products. Previously we tended to treat MS as a single group. Now, when you consider the oral category, VUMERITY is basically the sole branded medication left in that space. Through wise spending, we found we could actually expand that brand pretty effectively. As a result, moving forward, we're adding it to our growth products. Take just the medicines introduced since 2023 — those four, Lekembi, Skyclaris, Xerxuve, and Calcadi — they're currently generating over a billion dollars in revenue, and their growth has been really robust too. Meanwhile, in the MS division, we still brought in $3 billion. So looking at commercial results, I'd say Biogen is running and firing on all cylinders, and doing very well. When I look at 2025, what stands out most is how far our pipeline has come. Later on, Priya is going to walk through a chart showing that pipeline, and it has expanded significantly throughout the year. During this year, we anticipate several important readouts that could be iClick — I'll circle back to that point. That one is currently under review in The US, Japan, and China, and as you're aware, in the US we got a priority review along with a PDUFA date of May 24. As for Lidofilumab, a significant new therapy for lupus, the FDA has given it breakthrough designation for the cutaneous type of lupus. So we're starting to grow what's in our earlier-stage pipeline. A BTK degrader went into clinical testing at the start of this year. I'd add, too, that when we bought Alcion Therapeutics, that deal should meaningfully better the experience for people receiving injections. From what a lot of the physicians I speak with say, SPINRAZA delivers strong efficacy, yet eventually patients start viewing the intrathecal route as an issue. Here's a chance to swap out the intrathecal approach for a delivery method that's far more convenient. On top of that, we've kept active in business development, and during the fourth quarter we formed a fresh collaboration involving Vanqua and Dara Therapeutics. Moving to the following slide, Leukembi continues to hold the top spot, and it can maintain that position, commanding more than 60% of the anti-amyloid therapy market. I'd like to remind everyone that we usually prefer to examine new Rxs as a way of gauging a launch. In this particular case, though, that might not be the ideal metric to look at, because the competing product is genuinely administered therapeutically only for a brief period. On top of that, only the can truly has a maintenance indication. So here, I think total prescriptions are actually the finest measure, and that's precisely where Lucanbi clearly stays the market leader. So this year, we hope to get approval for the iClick. Last year, we secured approval of the iClick for maintenance. Along with locking in that maintenance indication, that alone is a big deal. A lot of patients are now finishing up the plaque removal stage, and the persistency figures show that about 70% of them stay persistent. In other words, these are people who continue treatment after reaching the plaque removal point. The iClick launched in October. It falls under Part D reimbursement, and full reimbursement won't be in place until 01/01/1927. Still, any patient who wants it can apply for formulary exemptions. From what we've been told, nearly everyone requesting it seems to be getting it. To be honest, we lack solid information on that front. That said, the iClick for induction might truly transform things. Dananemab has a competitive edge in that it's given as an infusion once a month, while ours requires an infusion every two weeks. When you move to a subcutaneous shot, infusions stop being part of the picture entirely. And we're definitely picking up on stories about folks wanting to travel and not always being in a position to drive those long distances to infusion centers, so in our view the iClick may well open up an entirely fresh opportunity and definitely ease the burden on neurologists. Remember, roughly 500,000 people receive a new Alzheimer's diagnosis each year, and there are really only 13,000 neurologists. If we can make this care path easier on both the physician and the patient, our hope is that throughput gets a boost. With blood-based diagnostics being used more, we're already seeing growth in the share of patients whose diagnosis is validated and who are in fact eligible for therapy — that figure has risen from roughly 50% to 70%. So all of these things, I think, are moving in the right direction. As a reminder to everyone, the market for anti-amyloid therapy has more than doubled. And I think we're seeing growing — we're certainly hearing a number of stories from physicians that they're actually seeing benefit in patients. The CDR Sum of Boxes is basically a measure you'll find in clinical trials, not something clinicians use day to day. So, all of this, I'd say, points to this business continuing to grow. And as we head into next year, that growth could even pick up speed. Let's move to the next slide. Alright, so here's the thing — our whole effort has been about building a path to growth. And frankly, we see that growth coming from three distinct places. First, obviously, is broadening the reach of the new drugs we already sell. Those are the ones shown on the chart — that represents today — and, if you genuinely study that chart, apart from VUMERITY, every single one of them was not just first in class, but the first treatment ever to exist for those diseases. So what that means is we're entering with breakthrough medicines, yet we also have to build those markets ourselves. AKINBI — we've already discussed that one. With SPINRAZA, we managed to launch the high dose in Japan. What we're hearing early out of the Japanese market suggests we're actually surpassing what was expected on adoption. And we're even witnessing some switchbacks. We're eager to see additional data as it emerges. Europe comes next; and naturally, we've got a PDUFA date in April for the high dose in The US. Xerxuve genuinely caught every one of us off guard. Once again, our sales more than doubled in 2025; I believe this is also opening up people's grasp of how substantial the actual burden of postpartum depression is. And we're noticing quite a few well-known individuals, such as Jennifer Lawrence, and we had just been featured in surgery — we had just been featured in People Magazine.

Christopher Viehbacher

executive
#4

And this isn't just generating some commercial wins — I believe it's genuinely reshaping how postpartum depression is viewed. This condition remains heavily underdiagnosed: roughly 500,000 mothers each year deal with it, yet only around 80,000 receive a diagnosis, and even fewer, clearly, get treatment on zirzube. There's a genuine chance both to expand this market and, I think, to truly make a meaningful difference in postpartum depression. Skyclaris keeps expanding; we got approval in Brazil during the past year, and we aim to launch there this year. At this point we're launching this product in essentially every part of the world apart from Asia, obviously, since for genetic reasons this disease doesn't really exist there. Often, our patient counts run ahead of revenue, since we provide the therapy through early access initiatives and work out terms as we go. So my expectation is that we'll continue to see consistent forward movement. As with SPINRAZA, sales for these kinds of treatments can follow a rather uneven path. For my part, I like to examine a trailing twelve-month view when it comes to these. We deal in products characterized by low volume and high value. Consider SPINRAZA — in some nations, deliveries happen just one or two times within a given year. Because of that, shipment scheduling can distort what's really happening if your lens is only one quarter. But at this point, as you know, with those products expanding and having just described to you how impressive their performance has been, we now have an entirely new tier—an additional wave—of possible growth. That includes ladafilimab, with SLE results hopefully arriving before this year ends, plus velzartamab, which should produce AMR data possibly in the coming year. For Zorvenirsen, our partner Stoke has said they may be in a position to have a data readout during '27 too. With Dipirolizumab, one positive phase three is already in hand, and a second phase three is underway. Salineersen delivered remarkably compelling findings following phase two. We gave the treatment to kids who'd previously undergone gene therapy—say, as babies—yet by the time they reached four or five, they still couldn't sit or stand, and we did observe a few instances of that. Naturally, every bit of this needs verification through a phase three trial, and we've got one running. Beyond that, the preclinical work could also prove to be an actual game changer, right? We must keep in mind that for many, many years this condition remains silent prior to anyone developing symptoms, and during that entire stretch, patients are shedding neurons. It stands to reason, then, that if you treat people sooner and manage to keep as many neurons intact as possible, you ought to see some payoff. That is essentially the purpose of this study: by enrolling individuals in the early stages, can we demonstrate that symptoms might be stopped from ever appearing, or at minimum that the illness gets pushed far off into the future? This is an enormous undertaking. The trial began signing up participants in 2020. All slots are now filled, and our expected timeframe for reviewing results is 2028. As you can gather from all this, the study will be exceptionally demanding in its standards. It is destined to become a landmark trial. Not only will it matter commercially, but this truly represents pioneering science and will shape the whole neurology field. So and naturally, we continue putting money into earlier stage work. There are possible data readouts ahead for a few high risk, high reward efforts, such as the LARC two and in Parkinson's. We've got a novel modality that might prove very compelling — the anti tau ASO, which should also deliver phase two results during this year; and our research portfolio is getting real focus. I mentioned a number of the partnerships we've formed. There's the DTK. There's an a rack four for lupus that has now entered the clinic. We intend to bring in additional early stage BD arrangements, yet I believe we also have several more INDs that might reach the clinic across the next eighteen months. On to the next slide, please. So where does our attention sit in 2026, truly? Clearly, an important date awaits us with the LAKEMBY approval for the subcutaneous AI initiation, scheduled for May 24, and we will, clearly, be hoping that gets approved. There's also, with luck, the approval for the high dose regimen for SPINRAZA in The US, carrying a PDUFA date in April. There are a pair of Phase 3 trials we're running for lislelizumab, and I'd like to give Priya credit here, because there are approximately 55 additional lupus studies in progress, and Priya along with her group was able to accelerate the timeline. At first, the data wasn't anticipated before 2027. Speaking commercially, I'm always in favor of watching development accelerate, because that points toward stronger commercial prospects down the road. And finally, we're advancing that pre-POC pipeline where the risk is high and the reward is high. At this moment, I'd say our confidence in the late-stage pipeline is fairly solid, but the earlier-stage pipeline still needs to be bolstered. That leads us into our outlook for the entire year, measured on a non GAAP diluted EPS basis, which sits at approximately $15.25 up to $16.25. With that said, I'll now pass it over to Priya.

Priya Singhal

executive
#5

Thank you, Chris. The headway we've achieved in restructuring and overhauling our development pipeline gives me a lot of optimism. This slide makes clear that the bulk of these high-scientific-conviction, late-stage possibilities are fresh. They were brought in within only the past twelve months. And as we shared last quarter, we've sped up TOPAZ-two, our second SLE trial for litifolumab, which should now produce results before this year is over. Another thing this slide shows is that 2026 matters a great deal, marking the start of registrational data arriving across a span of multiple years, continuing for the next several years. And within merely the coming eighteen months, we might get data for nitifilumab in both SLE and CLE, plus talsadimab data in AMR. Every one of these represents a registrational readout. Significantly, as you're aware, we lately revealed that we'd obtained priority review for the Chembi iClick initiation, and we received breakthrough therapy designation for litifolumab in CLE. Seeing these programs gain outside recognition as potentially impactful is quite heartening; we also keep showing and stressing our scientific leadership. Not long ago we shared fresh data spanning several of our main franchises at medical congresses, among them gatherings held by the American Society of Nephrology and the American Epilepsy Society. During December, we additionally presented at CTAD, where we underscored how vital it is to keep using lukembi in a maintenance setting; and only this week, we published Pivotal Devote SPINRAZA high dose data in Nature Medicine. Taken together, all of this strengthens our conviction that our pipeline will keep playing an essential part in creating the new Biogen. Now shifting to our complete development pipeline. We think we've reshaped it into a portfolio that's better balanced throughout the risk-reward spectrum. This stems from a highly intentional effort we've conducted across recent years to drop lower-value projects and draw in fresh assets with potentially greater value. At present, our late-stage registration pipeline is made up of programs with strong scientific conviction and considerable commercial promise. That contrasts with how Biogen operated previously. It's likewise balanced against our early-stage pre-POC pipeline, which holds the high-risk, high-reward assets, where we keep pursuing the science to figure out what comes next. We stay committed to expanding our early-stage pipeline through both internal research assets and possible business development chances. Right now, we keep advancing by moving Big one forty five, our BTK degrader, into the clinic, having just launched a phase one study among normal healthy volunteers. And we keep seeking to possibly introduce additional INDs to our pipeline throughout the coming several years and months. Now looking ahead; and anticipating the next eighteen months, the quantity of expected data readouts and key milestones gives me real encouragement; and I'd like to call attention to a few of them now. Turning to SMA: we've secured approval for high-dose SPINRAZA in Europe and Japan, and we're waiting on a regulatory decision in the US in April. For salinersen, which in our view has the potential to reshape the standard of care in SMA, we plan to share compelling follow-up phase 1b data at next month's Muscular Dystrophy Association meeting. With ladifilumab and billing, following our breakthrough designation for CLE, we're now planning and getting ready to present new data from the phase 2 portion of the phase 2/3 seamless amethyst CLE trial at a medical meeting, hopefully during the first half of this year. On an exciting note for the Kembi, given priority review, we now anticipate an FDA for iClick initiation in May. Equally important, regulatory filings are also underway in Japan and China. Our view is that iClick represents a differentiated, important opportunity that could bring extra optionality to patients as this key market keeps expanding. We also anticipate data from our pre-POC pipeline for 122 in Parkinson's disease and BIB eighty in early Alzheimer's disease at some point around midyear; these datasets will help us decide how to move these assets forward. Above all, for 2026 we look forward to the ladufilumab phase 3 data in SLE, expected at the end of this year, and we remain encouraged by the opportunity in CLE, where we expect to see data around midyear next year. On a similar timeline, we'll begin to see data readouts for fezartumab in AMR. To wrap up, I hope you can see the growing momentum across our pipeline over the coming eighteen months, and we believe this will propel our goal of delivering the new Biogen. I'd now like to pass the call to Robin for an update on our financial performance.

Robin Kramer

executive
#6

I want to walk through several important points regarding the robust results we posted for both the fourth quarter and the entire year. Unless I say otherwise, every comparison I draw in these comments is against 2024 and relates to non-GAAP figures unless noted differently. Beginning with earnings, our non-GAAP EPS for both the fourth quarter and the full year 2025 landed above what we had anticipated. Non-GAAP diluted EPS for the fourth quarter totaled $1.99. For the full year, non-GAAP diluted EPS reached $15.28. As we had expected, our Q4 2025 GAAP and non-GAAP results included $222 million of IPR and D charges tied to fourth quarter business development transactions, among them license agreements with WANCA Bio and Dara Therapeutics plus the acquisition of Alcion Therapeutics. That produced a $1.26 effect on EPS. I want to note that roughly $180 million in one-time charges recorded during the quarter, connected to litigation and other matters, weighed on our GAAP operating income. We turned in a strong revenue performance for the year, and our growth products did well. They brought in more than $800 million during Q4 2025 and $3.3 billion across the full year 2025. That equals growth of 69%, in each case, against 2024. Beyond that, we keep seeing resilient results from our U.S. MS business. Total revenue for the full year 2025 came to $9.9 billion, which is 2% higher than 2024. Strong commercial execution paired with careful expense discipline allowed us to generate robust cash flow. Consequently, we produced $2.1 billion in free cash flow for the year and closed it holding $4.2 billion in cash and marketable securities. That gave our balance sheet further strength and gives us flexibility as we keep investing for growth. Now I'll discuss our Q4 revenue performance. During Q4, revenue from our growth products surpassed revenue from our MS business excluding VUMERITY, which sits within our growth products. Akembi kept experiencing consistent sequential demand gains worldwide, as fourth quarter end market sales booked by Eisai reached roughly $134 million, up 1054% against Q3 2025 and Q4 2024, respectively. But can be posted consistent sequential and year over year growth in the U.S. and internationally. Skyclaris recorded sequential growth in global patient demand, with Q4 global revenue of $133 million, a 30% increase year over year. Within the U.S., Q4 revenue was $89 million. That amounts to sequential growth of $14 million, helped by roughly $9 million of favorable inventory dynamics. We anticipate this inventory build will be drawn down in Q1 2026. Beyond the U.S., fourth quarter revenue of $44 million took a hit of approximately $12 million from net pricing adjustments. Looking ahead, we feel optimistic about future growth as we enter new markets. Global SPINRAZA revenue during the fourth quarter was $356 million. In the U.S., we were glad to see SPINRAZA grow year over year, with fourth quarter revenue of $169 million. Beyond the U.S., fourth quarter revenue of $188 million was affected by shipment timing. On the whole, SPINRAZA kept showing resilience in a competitive market, with full year revenue declining 2% year over year. Revenue for VUMERITY during the fourth quarter reached $181 million, propelled by consistent demand growth compared to the prior year, helped along by better affordability within The US owing to the IRA Part D redesign. Timing of shipments tied to that favorable inventory build we mentioned during our Q3 earnings call had a negative effect on Q4 U.S. Revenue. Across the entire year, VUMERITY brought in $747 million, which equals 19% growth versus the previous year. We're also glad to observe robust results from ZERZUVE and CALSADI, mainly because of higher demand. Regarding our other MS products, worldwide TESARBRI revenue for Q4 came to $398 million, showing ongoing resilience; within The U.S, we brought in $244 million of revenue. Revenue outside the U.S. totaled $153 million, where biosimilar competition affecting the IV formulation in The EU was partly counterbalanced by sustained demand growth for the subcutaneous version. TECFIDERA experienced the anticipated speeding up of generic erosion in The EU, and we anticipate that will persist in 2026. Our anti CD20 therapeutic programs produced $521 million in revenue during Q4 2025. That's up 12% compared to a year earlier. Royalties from Ocrevus largely fueled this gain, which gained from the subcutaneous launch. Now some remarks regarding the remainder of the 6% for Q4 2025 against Q4 2024 and ten percent across the full year 'twenty five versus the full year '24, chiefly because of ongoing cost reduction measures achieved through our portfolio prioritization initiatives and our Fit for Growth program, partly offset by our investment in our Phase III clinical programs such as selzartamab and litafilimab, which received partial funding from an R and D funding arrangement. 1% for Q4 and full year 2025 against 2024. Mainly because of planned prelaunch activity backing lupus and nephrology plus direct to consumer advertising for the Lekambi and VUMERITY. As I mentioned before, a $1.26 impact from our Q4 business development transaction is included in our GAAP and non-GAAP results. Our GAAP and non-GAAP tax rates during the quarter gained from the release of reserves when a statute of limitation expired. We're happy with the quarter along with our full year 2025 results. This solid commercial execution, combined with disciplined financial management, generated ongoing strong cash flow performance for both Q4 and full year 2025 with free cash flow reaching $2.1 billion for the full year 2025; and shifting to the balance sheet, consequently, we've further reinforced our financial position and ended the year holding $4.2 billion in cash and marketable securities, along with $2 billion of net debt. Financial strength gives us flexibility to back strategic investments as we aim to generate meaningful innovation for patients and long term value for our shareholders. Looking forward, we think the transformation activities undertaken thus far have laid a strong foundation for delivering on the vision of the new Biogen. One key piece of making this vision a reality is our dedication to putting money into prelaunch efforts in a strategic way to back our lupus and nephrology portfolio; our aim is to make certain we're properly set up for the portfolio that lies ahead while we stay focused on financial discipline. Since we anticipate our first Phase III data by the close of this year for liticilimab and SLE, and in the following year for falzartamab and AMR, we're committing essential funds right now so we're positioned to bring these products to market successfully; and simultaneously, we anticipate holding our core OpEx in 2026 about level with 2025. Now let's shift to what we expect for 2026. We anticipate full year non-GAAP diluted EPS landing between $15.25 and $16.25, which reflects growth relative to our full year 2025 results. For 2026, total revenue is projected to fall by a mid single digit percentage against 2025. Revenue gains from our growth products partly counterbalance competitive pressures in MS; for our MS product excluding VUMERITY, we anticipate full year revenue dropping by a mid teen percentage against 2025; we anticipate our full year contract manufacturing revenue to come in at approximately $300 million in each half of 2026. Shifting to the P and L; we anticipate gross margin coming in about level with 2025, And expanding on what I said about OpEx staying consistent for the year, we anticipate Q1 expense running about 10% above Q1 of last year because of how we're phasing spend in 2026. Please take a look at this slide along with our press release for additional key guidance assumptions; at this point I'll hand the call back to Tim for Q and A.

Tim Power

executive
#7

Thanks, Robin. Let's go to our first question, please.

Ruth

operator
#8

Thanks. For those of you joining by phone who want to pose a question, just hit star 1 on your keypad to let us know. Once more, that's star 1 to ask something. Our first question is from Alex Hammond at Wolfe Research.

Alex Hammond

analyst
#9

Hey everyone, thanks for letting me ask. I suppose this one's about Mackenzie. Could you help us think through how sales growth might be paced across this year? What we're really after is grasping the timing and the share of patients who will probably move on to maintenance, plus how that could affect revenue. Thanks a lot.

Christopher Viehbacher

executive
#10

Absolutely, thanks so much. As I mentioned, we lack solid figures on the actual count of patients transitioning to maintenance, given that all we track is vial sales. That said, what information we do have points to persistence running at roughly 70%. This implies a substantial group reaches the conclusion of the plaque removal phase and continues into maintenance. At present, the bulk of them remain on the monthly infusion, since you move from a biweekly infusion in the plaque removal phase to a once-a-month schedule once maintenance begins. We are, however, observing growing adoption of the subcutaneous pen. Yet again, reimbursement for it isn't complete, meaning patients must navigate the formulary exemption process. So my expectation is that you'll largely witness steady growth sequentially, quarter after quarter. Blood-based diagnostics are being used more and more, and as I noted before, that helps ensure patients who qualify for treatment actually get in front of a neurologist. A growing share of neurologists — our current estimate puts it at approximately 10 to 15 percent, though that figure should rise — are employing blood-based diagnostics to confirm the diagnosis. Hopefully this cuts down on the number of PET scans and lumbar punctures. There's a financial motive behind that as well. A PET scan runs roughly $5,000. A test's cost, I believe, sits at around $140. So economics will push things toward the blood-based diagnostic. Naturally, should we secure approval of the pen for induction, that would be a significant win. Still, I suspect we'll find that not all patients will switch over right away. For those who live in more rural areas, say, and face a lengthy drive to an infusion center, uptake could well be quicker. We've definitely heard physicians express a wish to keep bringing patients in, at minimum during plaque removal's early stage, so they can watch for potential ARIA and perform the MRIs. What we're hoping for, then, is that once the subcutaneous version wins approval for induction, and as payers begin reviewing their formularies for 2027, there's a solid likelihood some payers will adopt the subcutaneous form for induction as well as maintenance, with both gaining full reimbursement as of January 1. That really comes down to each payer making its own call, and we won't have visibility until formularies are published, later in 2025. So my sense is, as I mentioned, you'll keep observing that straight-line expansion. At the same time, though, we're seeing a quite robust reaction to our direct-to-consumer promotion. All those things are building on one another; we're definitely picking up anecdotal reports that doctors appear to value the improvement they're witnessing among their patients. So I'd say the first six months likely bring ongoing linear growth. At some point during the back half of 2025, and quite possibly extending into 2027, there's room for that to speed up. Still, I believe we genuinely need complete reimbursement in place so we can fully capitalize on the subcutaneous pens. Thanks, Chris. Rose, could we bring in Ruth—apologies. Shall we move on to the following question?

Ruth

analyst
#11

Yes. We'll go next to Phil Nadeau at TD Cowen.

Phil Nadeau

analyst
#12

Chris, I believe the main topic investors are discussing is the timing of when Biogen's revenue could get back to growing. What's your view on that? When might the growth products surpass the legacy franchises? And what part might business development play in Thanks.

Christopher Viehbacher

executive
#13

Well, up to now, over the past 2 years, the growth products definitely — certainly in the last year — exceeded the decline of EMS. Now in this year, we'll have a full 12 months of TECFIDERA generic erosion in Europe. We only had roughly 6 months of that during 2025. Due to that, my expectation is that we'll see a bit more deterioration in the MS portfolio. When last year ended, a biosimilar for Tysabri also entered the market. Since it's early days, we can't really determine the extent of that erosion. Still, I'd say we hold reasonably strong hope of maintaining a solid share of the market for the Tysabri brand. There exists a modest number of physicians who are firmly convinced of Tysabri's significance. So that's the group we will be counting on, you know. In addition, within our US company, we have a patient services organization that is amazingly strong. From my perspective, for us to truly return to a growth trajectory, two factors are essential. First, we must start witnessing favorable Phase III data readouts along with product introductions. So, supposing the Phase III trial of ladafilumab yields positive results in SLE, it might reach the market in 2028. And if we presume the AMR findings are favorable, that too could see a 2028 launch. In my view, AMR in particular might be a launch that ramps up rather swiftly, simply because of the established patient population that's already identified and the absence of any existing therapy. The second factor, naturally, is BD, and we continue searching for possible acquisition targets. The businesses we're talking about have already reported phase III data and are either just beginning or in the earlier days of selling their products commercially. Right? And they're definitely valued at roughly $5 billion, somewhere in that 5 to $6 billion range; however, the truth is that locating assets which truly create value for our shareholders is difficult. Such companies do exist, yet we have not identified one we could buy at a price we believe is sensible for our shareholders, though we keep searching. Every single day we're out there scanning the market, and to my mind that represents an opportunity. That said, I'd add that our confidence is fairly strong when it comes to the late stage pipeline we hold. As everyone knows, nothing in R&D is guaranteed. Still, reaching 10 phase three programs over the past year is a genuine accomplishment, because back in 2024, ladifilumab was all we had. So today, beyond having those programs established, we also have whatever BIB 80 and LARC two may yield, and additional programs are starting to enter the clinic. We continue to assess things, yet the truth is that the launches of these products matter most, along with whether we can secure an acquisition. If that doesn't happen, I believe we've nonetheless created that bridge to growth. Cash keeps flowing in, and profits keep flowing in. And we're putting substantial money behind our growth brands.

Tim Power

executive
#14

Thanks, Chris. Let's go to the next question, please.

Ruth

analyst
#15

Brian Skorney from Baird is our next caller with a question.

Brian Skorney

analyst
#16

Looking ahead to the BIB080 catalyst, I was hoping Chris or Alicia—if she happens to be joining—might offer some thoughts. You've clearly had a lot of success with SPINRAZA given as an intrathecal injection, and that's held up despite oral competitors; yet with Leukembi in Alzheimer's, things have proven far more difficult using an IV, which I believe most people would say is the simpler way to give a drug. Compared with intrathecal. So how should we frame the commercial potential for 80? And which clinical results are truly required? Beating LeCambi? to get a sense of the next tier of commercial opportunity?

Christopher Viehbacher

executive
#17

Honestly, we want to actually look at the results. What I can share is that neurologists are going to examine this information quite carefully too. Each Alzheimer's specialist I speak with genuinely believes tau represents a key target, and when you consider how severe Alzheimer's is, that tracks with how much tau is present. So that logic holds. And using BIB 80, we're aware that we can in fact lower tau. What remains unknown is the duration of tau reduction needed before cognition starts to shift; and I think the GLP one findings have shown just how difficult it is to shift cognition at that level; so my view is we should first examine the results, and if there's something there, you'd also want to understand the safety profile. Some believe ARIA won't be an issue for us. Still, we have to review that information. These are phase two results representing genuinely breakthrough science. No one can say for sure. So far nobody has managed to shift the needle. We also hold the view that what counts is tau inside cells rather than tau outside them, and that explains why the antibodies failed. Alzheimer's, to me, is a complicated illness, and typically complicated illnesses call for several different approaches. From a business standpoint, then, there's clearly already plenty of guessing about how these therapies might be ordered. Would tau be addressed first? Would abeta be addressed first? Might they be combined? And there's another opening once the results are in. Could you expand into additional tauopathies? So saying anything definite now is premature, though I can say that should the outcome be positive, I expect the neurology field will be extremely enthusiastic. That said, I'd want to remind everyone that we'd still need to run a phase three program, and nothing in Alzheimer's moves especially fast. Completing that phase three and getting the product to launch would once more require a number of years.

Tim Power

executive
#18

Thanks, Chris. Let's go to the next question. Thanks, Ruth.

Ruth

operator
#19

Yes. The following question is from Michael Yee at UBS.

Michael Yee

analyst
#20

Hey, everyone. Appreciate the question. Turning to Bib 80, which I believe will be a truly significant readout. As I understand it, the primary endpoint involves CDR some of the boxes at 18 months, which is excellent; and I think the trial is well designed; but how crucial is examining subgroups, for instance, high tau versus low tau or any of those prespecified — how crucial is the tau sub study where, clearly, PET tau imaging will be critically important to determine whether we're actually doing Thank you.

Christopher Viehbacher

executive
#21

Priya?

Priya Singhal

executive
#22

Thanks, Michael. No, it really matters a great deal. As Chris just laid out, I'd say this represents a highly significant examination of the scientific hypotheses. So we're going to be examining tau PET. We're going to be examining fluid biomarkers. We're going to be searching for trends along with clinical data, and we're going to attempt to triangulate all of that. And crucially, I think we've structured it effectively, since we do have a tau sub study; and as I'll simply remind everybody, we are testing. We're testing 3 doses along with 2 dosing regimens. And it is a randomized controlled trial. So every bit of that is going to be quite informative. We believe this is going to be very important to assess. Yeah. All of it.

Tim Power

executive
#23

Thanks, Priya. Let's go to the next question, please.

Ruth

analyst
#24

Yes. We'll now go to Salveen Richter at Goldman Sachs.

Salveen Richter

analyst
#25

Morning. Appreciate you taking my question. Looking at the registrational pipeline in late stage, that entire basket has been placed under high conviction by you. And I just want to get a sense, in the case of lixilimab, with those phase three trials reading out, plus the somewhat mixed phase two datasets, and just the inherent risk surrounding lupus, what makes you think this is high — that your conviction is high regarding the phase three outcomes?

Priya Singhal

executive
#26

Thanks, Salveen. Let me begin by saying we truly regard ladasolumab as a scientific conviction late stage program. The reason is that it goes after the b d c a two pathway, as you're aware; and we know b d c a two is actually a receptor expressed solely on what we call the PDC cells, human plasma cytoid dendritic cells, which regulate immune response and then control the type one interferon signature pathway; and I think what we've demonstrated, and this has been published by us in the New England Journal of Medicine, both parts of the LILAX study where, in the study's first part, systemic lupus was examined by us, and in the second part, cutaneous lupus was examined by us. And in both separately, we believe we had important data that we would classify as proof of concept. So I think the trials were designed by us to really assess that and confirm that. Our primary endpoint is also similarly, you know, established as SRI four, which is the SLE responder index; and what matters about this primary endpoint is that it calls for a more than a four point or greater reduction with no worsening. So it truly captures disease activity; and I think because of the pathway, which is highly relevant for skin and joints, our inclusion in the litifilumab topaz one and topaz two trials has been targeted by us to be really appropriate for the mechanism of action; so overall, we stay encouraged and optimistic. Naturally, we must wait for the readout. And, again, the readout for SLE is end of the year. And CLE will be sometime midyear next year.

Tim Power

executive
#27

Thanks, Priya. Let's go to the next question, please.

Ruth

analyst
#28

Yes, we have a question from Umer Raffat with Evercore.

Umer Raffat

analyst
#29

Good morning, everyone, and thanks for taking my question. Perhaps I'll shift direction to selzardimab for a brief moment. How crucial is it for you to achieve success on the EGFR endpoint in addition to the primary endpoint? I ask this because, back in phase two, evaluating that endpoint proved difficult due to the substantial imbalance on EGFR. And regarding this pelsartan map point two, I suppose, do you consider narrowing the development scope to only kidney transplant AMR? Why not pursue AMR plus other organ transplants too? Thank you very much.

Priya Singhal

executive
#30

Thanks a lot. Overall, I believe it's a highly significant endpoint. As we've structured it, the primary endpoint is what we'll concentrate on, though we will certainly examine all secondary endpoints. Ultimately, as tends to happen in most situations, the full body of data will be what counts. We stay very enthusiastic about it given the proof of concept. It was a small study, yet the effect size exceeding 80% observed in that modest phase two study was truly compelling. That, I think, is the element that is quite encouraging. Turning to other transplants, I appreciate that, since we ourselves are assessing how the c d addressing the c d 38 autoantibodies performs in other transplants. So it continues to be a key focus of internal assessment and inquiry; and, as you know, we'll share more once this gains importance. I also wish to highlight that we have, you know, we are currently starting another sister indication study involving microvascular inflammation, which we believe will be a very important component as we keep considering, you know, what patients and prescribers truly require in the antibody mediated rejection space.

Christopher Viehbacher

executive
#31

Right. I guess the one point I'd tack on is that we know there are certain doctors out there trying CD38 on their own. There's one physician I'm aware of, for instance, working in heart transplant, and clearly we'll be keeping an eye on quite a bit of that work; none of it is under our sponsorship, but we'll definitely be aiming to pick up whatever lessons come out of the experience those physicians have.

Tim Power

executive
#32

Can we go to the next question, please?

Ruth

operator
#33

Absolutely. Moving on, our following question is from Evan Seigerman, who is with BMO Capital Markets.

Evan Seigerman

analyst
#34

Hey, everyone. We really appreciate you taking my question. I'd like to discuss HD SPINRAZA and the possible U.S. approval that's arriving in April. Regarding your rare disease business, how should we view the impact that might have on top line growth for 2026? Thank you.

Christopher Viehbacher

executive
#35

As I mentioned earlier, Japan became the first nation to grant approval. Once more, we're observing stronger results right out of the gate. Since we're only a few months into the launch, drawing firm conclusions is tough, yet we are definitely off to a better beginning than we'd anticipated. And that's not only regarding adoption, as I noted, but also with switchbacks. As you know, we've clearly witnessed considerably greater efficacy levels in the study, which points to a bigger benefit from reaching a therapeutic level more quickly. I'm aware that in Europe our teams are quite eager about the launch, they'll be next to go, and we'll see how that turns out; and, you know, the response once more is that the community has been anticipating these data. So what matters most in the SMA market is really efficacy as opposed to convenience. You know, the majority of physicians I speak with, and I enjoy going to talk with physicians who prescribe SPINRAZA globally; and when you inquire about efficacy, most of them think it's truly SPINRAZA. But, you know, at a certain point, the convenience of the oral begins drawing patients in. Now in this case, we're going to be substantially raising the efficacy level, and I believe the decision between oral and efficacy will become tougher for certain physicians and parents. Market research indicates there might be a sales increase, but I'd say nothing beats actual sales when it comes to market research; so I believe there's a chance for upside here. How quickly physicians will be ready to move patients over is something I think we must wait and see about, practically speaking. But it's a significant launch. And, once more, it's been eagerly anticipated by patient advocacy groups along with the physician community.

Tim Power

executive
#36

Ruth, can we go to the next question, please?

Ruth

operator
#37

Yes. Our next question comes from Brian Abrahams at RBC Capital Markets.

Brian Abrahams

analyst
#38

Hey. Morning. Congratulations on the progress, and thank you for taking my question. There's a slide you have that lays out certain prelaunch activities. I guess I wanted to ask whether you might walk us through what happens on the ground when it comes to pivoting and redeploying the commercial infrastructure that already exists, ahead of the possible lupus nephrology launches, and while it sounds like the cost structure won't shift much in this year, broadly speaking, I'm curious how you'd anticipate commercial investments needing to develop over a longer horizon to underpin the potential growth you're bridging to? For instance, is there a long term margin target?

Christopher Viehbacher

executive
#39

Well, the first item is gaining experience and capability. Since we're moving into areas where Biogen hasn't been there before. You know, with AMR, we'll be calling on transplant nephrologists. With IGAN, we'll be calling on nephrologists. With lupus, we'll be calling on rheumatologists. And, so in each of these, and, of course, beyond the US, we'll be calling on epileptologists and neurologists. So we have to develop capabilities; and there, you know, I think I'm very encouraged. Market research is always difficult because it's somewhat theoretical for physicians. So one of the proxy indicators I look at is whether we can draw top talent. And we've recruited a number of people from companies that already have a strong footprint in those areas; and, you know, when you're staking your career on a product, I think that's a significant step for people. And so those joining Biogen are joining because they perceive potential in these products; so I'm already encouraged by that. But the fascinating thing is, I recall when we were developing Dupixent, you know, every one of the indications that DUPIXENT has today, are areas where Sanofi had no experience previously. And yet, in fact, by hiring really not very many people in medical and commercial. Sanofi's clearly turned that into a successful product; and the reality is that you don't need to have the full team necessarily possess that experience. You need to have sufficient medical capability; and on the commercial side, at least the commercial leaders with that. So I don't anticipate that this is going to have a massive impact on our OpEx trajectory. But it matters that we have people who understand these spaces because as I always say, if you've launched one product, you've launched one product. There are so many differences, between physician types, the patient. We have to truly understand the patient journey; so today, we're investing mostly actually in market research. We're going to be obviously present at congress and presenting the data as they come along. But it's really about preparation, first globally and then step by step regionally and locally, and at this point we aren't really expecting to see any significant shift in, as I mentioned, the actual amount being invested.

Robin Kramer

executive
#40

Yeah, Chris, one thing I might add is that wherever possible, we aim to shift resources away from our legacy business and toward our growth products — those already launching as well as the ones in the pipeline where we might get the chance to bring them to market.

Tim Power

executive
#41

Let's go to our next question, please.

Ruth

analyst
#42

Operator (Ruth): We're ready for the next caller, from Oppenheimer, that's Jay Olson.

Jay Olson

analyst
#43

Nice work on the quarter, and I appreciate you fitting us in. I'd like to ask something on the financial side, picking up where part of Brian's inquiry left off. What we'd like to understand is the margin on the Lycanby product. Could you describe how much expense is going into Lycanby? In what way does that stack up against your longer-term aspiration? Also, once things settle, what product margin does Lakenby target? Thanks.

Robin Kramer

executive
#44

Sure. We don't disclose the particular product margin tied to the But similar to what happens with nearly all products at launch, as we move further into the launch and keep improving our manufacturing processes, our expectation is that margins would improve across the near to mid term.

Christopher Viehbacher

executive
#45

Sure. As with the majority of products, honestly, revenue is what will ultimately determine this, correct? I mean, we're definitely still putting a lot of money into research and development. There's our AHEAD three four five trial. We've been working on the subcutaneous versions, and every one of those matters enormously for the can be's progress. On the commercial side, we're still spending quite a bit. Once again, this is a space where we have to build the market and educate people; so I wouldn't really anticipate seeing the OpEx level grow across the board, but if margin expansion does happen, it would be due to revenue beginning to catch up to that OpEx level, so to speak. Therefore, my view is that margins ought to rise over time provided that revenue keeps climbing.

Tim Power

executive
#46

Thanks, Chris. Let's go to the next question, please, Ruth.

Ruth

analyst
#47

We're going next to Eric Schmidt from Cantor.

Eric Schmidt

analyst
#48

Thank you. Perhaps a follow-up for Robin regarding how we redeploy capital. The balance sheet is substantially healthier than previously. You continue generating significant cash flow. And Chris just expressed considerable confidence in the pipeline, which includes the late stage pipeline. Is now the appropriate moment for a buyback of shares or some other method of returning capital to shareholders? Thanks.

Robin Kramer

executive
#49

Yes. Regarding capital deployment, our emphasis is on using capital in a way that drives long term shareholder growth. As Chris noted, we intend to put capital toward business development transactions. However, we consider capital deployment broadly, so a share buyback is not out of the question that we might consider. Yet right now, our main focus is on expanding that top line.

Tim Power

executive
#50

Thanks, Robin. Let's go to the next question, please.

Ruth

analyst
#51

Right. We're going next to Chris Schott at JPMorgan.

Chris Schott

analyst
#52

Thanks a lot for taking the question. Mine's a broader one about the pipeline. Chris, I realize that one thing you wanted to accomplish when you came aboard was building a pipeline that's more balanced. In the late stage, it certainly appears you've been accomplishing that. When it comes to the earlier stage, though, could you say a bit more about what your priorities are? Should we be expecting a greater number of these assets that carry big risk alongside big reward, and is that portion of the pipeline something we ought to view through that same balancing lens?

Christopher Viehbacher

executive
#53

Does that happen gradually? No. I don't think that, as an organization, we have the scale needed to play in that high-risk, high-reward arena. That said, we do possess substantial capabilities, including in Alzheimer's and ALS. With ALS specifically, our view is that we can keep putting money into it while avoiding excessive risk, since neurofilament serves as a key biomarker for us at least. That means we expect to learn fairly early whether a molecule is actually doing its job in ALS. As a result, the risk profile drops considerably—though the potential payoff remains very large, clearly, if you could deliver something for people with sporadic ALS. So that's an area we have not walked away from. Actually, there are a number of preclinical targets we're actively pursuing. When it comes to Alzheimer's, our belief is that this will be a central pillar for Biogen moving forward. Beyond tau, we're also exploring additional areas and mechanisms. That said, our neuroscience efforts are basically limited to that. MS is still in the picture — we do have work underway there — but the unmet need in MS has become fairly narrow at this point. What remains is really progressive MS, which is a hugely important unmet need, though it's also proven to be an incredibly tough target to crack, so our MS work is somewhat limited. Nearly everything else at the early stage, however, is focused on immunology. Immunology is clearly a huge area. I'd put it this way: looking out about five years, our focus remains firmly on rare immunology, which elsartanib and several other products have demonstrated for us. Once you move further back into earlier stages, though, I believe we can widen our scope considerably. Consider something like a Dera, or the VANQUA as well — each represents a chance to build both a portfolio and a product, and that's what makes immunology so compelling. The reason is that when you trace these immune pathways, you'll end up with one main target. After you've addressed the safety concerns and gotten that risk under control, running signal-seeking studies in other areas tends to be fairly affordable. That's one of the things we've been watching, because for a company our size, this is a very cost-effective area. And for the most part, I'd say immunology will likely draw a good deal more activity than neuroscience will. That being said, like I said earlier, ALS, Alzheimer's, and MS to a certain degree are still things we're aiming at.

Tim Power

executive
#54

Appreciate that, Chris. We’ll take one final question now. Joining us on the line is Danielle Brill from Truist Securities.

Danielle Brill

analyst
#55

Hi, everyone. Morning. I really appreciate you taking the question. There may be a few modeling points to go over. You brought up the one-time reimbursement true up related to Skyclaris — what size was it, and what's the right way to model the quarterly run rate for '26? Also, for XERZUVEY, how should we think about what the European rollout will do? Thanks.

Robin Kramer

executive
#56

Sure. Regarding Skyclaris, the true up that happened in Ex US came to $12 million, and I'd view it as tied to what took place during the fourth quarter. As Chris has said before, when we launch Ex US, reimbursement happens country by country, so booking timing shifts until that reimbursement is finalized. Because of that, from time to time you can get true ups or adjustments to estimates. In this case, though, it involved two countries in Europe, and it was a one-time item during the fourth quarter.

Christopher Viehbacher

executive
#57

Yet I believe you're going to keep witnessing solid, consistent expansion for Friedreich's ataxia. This remains, in our view, a significant opportunity. Plenty of patients are located in South America, so the Brazil launch strikes me as especially key for us; that will begin in the private market, and then state reimbursement will come on progressively as well. You know, Xerxovay, XERZUVEY is going to be intriguing in Europe. At first, the pricing assessments we were getting back meant it didn't make sense. But I think one thing we've observed from the success in The US is that a portion of that is carrying over into Europe too. Our plan is a very targeted launch across Europe rather than covering the whole continent, because of the issues around pricing. That said, the price points we're already observing look adequate to support a launch. Naturally, we're keeping the MFN situation very much in mind. Although our company isn't among those that have signed an agreement, the administration has, as you know, started demonstration projects. So whenever we bring out new products, we're definitely evaluating things through an MFN lens. So that means we'll likely kick things off in roughly three to four nations, rather than all twenty-seven.

Tim Power

executive
#58

All right, that brings the call to a close. I appreciate everyone taking the time to join us today. Should you have any additional questions, feel free to get in touch with anyone on our IR team. Thanks so much.

Ruth

analyst
#59

Ruth (Question): That wraps up our session for today. We appreciate everyone joining in. You're free to leave the line now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.